Sernova Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes

Sernova’s Cell Pouch (TM) with transplanted islet cells reached primary safety measurements and clinically significant efficacy outcomes including glucose-stimulated C-peptide and the release of insulin in the first patient transplanted  Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that in an interim analysis of its human Phase I/II clinical trial, Sernova’s Cell Pouch…

Sernova to Present Interim Data from Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant Association

Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company is pleased to announce that Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, will present, in an oral podium session, early preliminary data and observations from Sernova’s ongoing clinical trial, entitled A Safety, Tolerability and Efficacy Study of Sernova’s Cell…

Sernova Announces Collaboration to Advance Therapeutic Cell Pouch Technologies for the Treatment of Hypothyroidism

Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical- stage regenerative medicine company announced today a collaboration with the University of British Columbia’s, Dr. Sam Wiseman for development of a Cell Therapy-based Program for the treatment of hypothyroidism. This collaboration is funded by a Transplant Venture Grant awarded by the Transplant Research Foundation (TRF) of British…

Renix Successfully Commissions the Demonstration RenixUIX™ Unit

Renix understands the need to provide cost-effective and sustainable solutions to capture, separate, and purify resources for the increasing needs of the global population. The world’s producers and providers need these solutions to face the looming technical and economic pressures associated with lower grade sources, increased regulation, and increased environmental and social licensing issues. As…